Bentham Science Publishers, a major STM journal publisher of 130 titles, answers the information needs of the pharmaceutical, bio medical, engineering and technology research community. Leading journals include Current Gene Therapy (Impact Factor 2.738), Current Alzheimer Research (Impact Factor 3.145) , Current Medicinal Chemistry (Impact Factor 3.455).
Beckman Coulter Life Sciences is dedicated to improving the health of people around the world. The company’s global leadership and world-class service and support delivers sophisticated instrument systems, reagents and services to life science researchers in academic, commercial and industrial laboratories, enabling new discoveries in biology-based research and development. Beckman Coulter has long been an innovator in laboratory automation, centrifugation, flow cytometry and particle characterization. For more information, please visit Beckman.com.
Antibody Solutions , founded in 1995, is an industry leading CRO that offers products and services with a focus on antibody-driven research, diagnostics and therapeutic applications tailored to each customer’s specific needs. We serve biotechnology, diagnostic and pharmaceutical companies, as well as universities by providing innovative antibody products and services. Antibody Solutions' approach to custom antibody discovery projects is client-centric and data driven.
Biomodels LLC is a preclinical contract research organization, that conducts predictive and translational studies for biotechnology and pharmaceutical companies in the areas of cancer, cancer supportive care, inflammatory and pulmonary diseases, in addition to several other clinical indications. Biomodels specializes in (non-GLP) efficacy studies that optimize dose, schedule, and define mechanism of action.
Aragen Bioscience, Inc. is focused on accelerating antibody and other large-molecule product development. Our integrated preclinical research offerings include: antibody discovery, antibody humanization, recombinant protein production and purification, stable cell line development as well as cell-based assays and in vivo models-of-disease. Our team has been chosen for their scientific experience and diversity. We pride ourselves in our ability to understand each client’s unique needs, both, from a scientific as well as business perspective. This enables us to be not only a high-quality service provider, but also a preferred R&D partner. We’re located in the San Francisco, Bay Area.
7847050 CANADA Inc.
The Editorial Society of two Journals- European Journal of Gynaecological Oncology (EJGO) and Clinical and Experimental Obstetrics & Gynecology (CEOG) – was founded in 1973 and operated until 2012 when it became 7847050 CANADA Inc.
The objective of the two Journals is the natural diffusion of scientific contributions originating in Italy, Europe, and throughout the world in the areas of gynecology and obstetrics, and in the area of gynecological oncology, for which a Journalin the latter has been dedicated.
EJGO is now celebrating its 37th year and CEOG its 43rd year.
One of the main goals of the Society is to promote international and cultural communications, while bringing together gynecologists and oncologist from Western and Eastern countries, while publishing the evolution in the areas of specialization.
BioAspect Preclinical Research Services specializes in conducting efficacy and proof-of-principle studies in cellular, transgenic drosophila, and rodent models of human diseases to identify health benefits of pharmaceutical, biotechnology, and nutraceutical products. We offer drosophila and rodent models of neurodegenerative diseases, ageing, longevity, addiction, obesity/diabetes, cancer, and natural health products. We also offer behavioural testing protocols in both drosophila and rodents.
BioAspect Products provides over 500,000 reliable research tools (ELISA kits, recombinant and native proteins, antibodies, competent cells and PCR products) to help new ideas grow and discoveries happen.
IIAM is a world-leading provider of non-transplantable, healthy and diseased, human organs and tissues for medical research, education and development. These tissues are recovered with minimal ischemia, stored in preservation and delivered in 12-24 hours to qualified researchers, scientists, healthcare and biotech professionals for medical advancement. Visit our website, www.iiam.org.
Mass Medical Angels (MA2) is a seed stage investor group exclusively focused on life science and healthcare investments. Our mission is to bring more clinical tools to the marketplace, while attaining superior returns for our investors. To do this, we provide financing and mentoring to early-stage life-science companies so that they can obtain further funding, reach positive cash-flow or be acquired. MA2 is collaborative and well connected, ready and willing to bring its many varied resources to bear in the service of its portfolio companies. We invest in medical devices, therapeutics, diagnostics, health services, health information technologies, and relevant research-related tools including laboratory equipment.
Diffinity Genomics, a unit of Chiral Technologies, has developed proprietary absorption resin that caneffectively cleanup PCR fragments in just one minute using our functionalized pipette tips.No additional reagents, consumables and equipment are required.
The Diffinity RapidTip® and RapidTip 2 for PCR cleanup remove dNTPs, primers, primer-dimers and DNA polymerase from PCR-amplified fragments for downstream applications, such as genotyping, restriction digests, cloning, and Sanger cycle-sequencing reactions.
In collaboration with Kaneka, we also offer the Diffinity DNA RapidExtract™ kits designed to lyse DNA in a single-incubation step in 10 minutes to yield PCR-ready DNA.
Biomere is a preclinical CRO based in Worcester, MA focused on early discovery drug development. In Vivo models range from rodents to NHP’s, specializing in autoimmune, metabolic and cardiovascular diseases. Specific models range from MS, colitis, lupus, diabetes, inflammation and thrombotic-related disorders. We have a variety of proprietary rodent modelsfocused on autoimmune disease and diabetes as well as providing supportive colony breeding and maintenance and on-site client room use agreements. Our NHP program maintains a sizable and growing colony of naive and non-naive NHPs for standard PK/PD studies along with sponsor-dedicated colonies aimed at providing high-quality and rapid study starts. Biomere has been serving the Bio-Pharma community for 20 years.Visit us at: www.biomere.com.